MedPath

The impact of blood glucose monitoring in youth aged (0-25Yr) with type 1 diabetes in managing diabetes and improving quality of life

Not Applicable
Conditions
Health Condition 1: E108- Type 1 diabetes mellitus with unspecified complications
Registration Number
CTRI/2023/01/049112
Lead Sponsor
JDRF
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Open to Recruitment
Sex
Not specified
Target Recruitment
0
Inclusion Criteria

Diagnosed with type 1 diabetes

Using insulin injections

No other medical condition

Exclusion Criteria

Other types of diabetes ( Type 2 diabetes, MODY, GDM, secondary diabetes )

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
To quantify the impact on glycaemic control and treatment satisfaction when people living with type 1 diabetes are commenced on the SWIIM program. The primary outcome is change in HbA1c from baseline, every 3 months till 12 months. This will be reported as a change in HbA1c as mmol/mol and %. A change of 11mmol/mol (1%) will be considered significant. <br/ ><br> <br/ ><br>Timepoint: HbA1c results at baseline and every 3 months after that till the completion of the study
Secondary Outcome Measures
NameTimeMethod
Secondary outcomes will be the incidence of severe hypoglycaemia, diabetic ketoacidosis and hospital admissions. These will be reported as the number of episodes per 100 patient-years <br/ ><br> <br/ ><br>Timepoint: The frequency of acute complications like hypoglycemia, DKA, and admission to the hospitals will be compared prior to the start of the SWIIM programme
© Copyright 2025. All Rights Reserved by MedPath